Skip to content

Patisiran

Onpattro (patisiran) is an oligonucleotide pharmaceutical. Patisiran was first approved as Onpattro on 2018-08-10. It has been approved in Europe to treat familial amyloidosis. Onpattro's patents are valid until 2035-08-27 (FDA).
Trade Name Onpattro
Common Name Patisiran
Indication familial amyloidosis
Drug Class
Patisiran
Get full access now